Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study - Christina Guo, Maxime Chénard-Poirier, Desamparados Roda, Maria de Miguel, Samuel J. Harris, Irene Moreno Candilejo, Priya Sriskandarajah, Wen Xu, Mariana Scaranti, Anastasia Constantinidou, Jenny King, Mona Parmar, Alison J. Turner, Suzanne Carreira, Ruth Riisnaes - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Elsevier, The Lancet Oncology, 11(21), p. 1478-1488, 2020

DOI: 10.1016/s1470-2045(20)30464-2

Links

Tools

Export citation

Search in Google Scholar

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Journal article published in 2020 by Christina Guo, Maxime Chénard-Poirier, Desamparados Roda, Maria de Miguel, Samuel J. Harris, Irene Moreno Candilejo, Priya Sriskandarajah, Wen Xu, Mariana Scaranti, Anastasia Constantinidou, Jenny King, Mona Parmar, Alison J. Turner, Suzanne Carreira, Ruth Riisnaes and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO